<DOC>
	<DOCNO>NCT01686945</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) , pharmacodynamics ( effect investigate drug body ) multiple dose long-acting GLP-1 analogue ( oral semaglutide ) carrier healthy male subject male subject type 2 diabetes ( T2D ) .</brief_summary>
	<brief_title>Investigation Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Doses Long-acting GLP-1 Analogue Healthy Male Subjects Male Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject , consider generally healthy , base medical history , physical examination , result vital sign , electrocardiogram ( ECG ) laboratory safety test perform screen visit , judge investigator . This also apply subject T2D , except underlie diabetes without associate hyperlipidaemia and/or hypertension Body mass index ( BMI ) : ) Healthy subject : equal 20 30 kg/m^2 . b ) Subjects T2D : BMI equal 20 equal 37 kg/m^2 Glycosylated haemoglobin ( HbA1c ) : ) Healthy subject : 6.0 % . b ) Subjects T2D : 6.5 9.0 % ( inclusive ) Additional inclusion criterion subject T2D : Male subject T2D ( diagnose within past 10 year ) treat diet exercise and/or stable dos metformin least 12 week prior Visit 3 ( Day 1 0 ) change treatment plan trial period History , presence , cancer , diabetes ( healthy subject ) clinically significant cardiovascular ( healthy subject ) , respiratory , metabolic , renal , hepatic , gastrointestinal ( GI ) , endocrinological ( except diabetes subject T2D ) , haematological , dermatological , venereal , neurological , psychiatric disease major disorder , judge investigator Blood pressure supine position screen examination : ) 140 mmHg systolic and/or 90 mmHg diastolic healthy subject . b ) 160 mmHg systolic and/or 95 mmHg diastolic subject T2D Use prescription nonprescription medicinal product ( except routine vitamin ) within three week precede dose . Occasional use paracetamol acetylsalicylic acid permit . . For subject T2D : Any current diabetes treatment apart metformin ( e.g . treatment incretin mimetics , Dipeptidyl PeptidaseIV ( DPPIV ) inhibitor , insulin secretagogues , insulin thiazolidinediones ( TZDs ) ) . Use blood lipidregulating agent , well blood pressure regulating , thromboembolic agent allow Exclusion criterion subject T2D : Proliferative retinopathy maculopathy require acute treatment determine funduscopy/fundus photography judge investigator . If subject present medical certificate funduscopy/fundus photography perform within last 3 month substitute funduscopy/fundus photography screen Nephropathy stag 3 5 , i.e . estimate glomerular filtration rate ( eGFR ) 60 . The eGFRshould determine use Modification Diet Renal Disease 4variable method encompass creatinine , age , gender , race Diabetic peripheral neuropathy use 10 g SemmesWeinstein monofilament examination great toe plantar aspect fifth metatarsal Clinically significant active cardiovascular disease include history myocardial infarction and/or heart failure ( New York Heart Association ( NYHA ) class III IV1 ) discretion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>